搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Escherichia coli O17:K52:H18 Phosphopentomutase (deoB) CSB-YP485486EOG
CSB-EP485486EOG
CSB-BP485486EOG
CSB-MP485486EOG
CSB-EP485486EOG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 UPF0246 protein yaaA (yaaA) CSB-YP485487EON
CSB-EP485487EON
CSB-BP485487EON
CSB-MP485487EON
CSB-EP485487EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 Non-specific ribonucleoside hydrolase rihC (rihC) CSB-YP485488EON
CSB-EP485488EON
CSB-BP485488EON
CSB-MP485488EON
CSB-EP485488EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 Glutathione-regulated potassium-efflux system ancillary protein kefF (kefF) CSB-YP485489EON
CSB-EP485489EON
CSB-BP485489EON
CSB-MP485489EON
CSB-EP485489EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 4-hydroxythreonine-4-phosphate dehydrogenase (pdxA) CSB-YP485490EON
CSB-EP485490EON
CSB-BP485490EON
CSB-MP485490EON
CSB-EP485490EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 Protein MraZ (mraZ) CSB-YP485491EON
CSB-EP485491EON
CSB-BP485491EON
CSB-MP485491EON
CSB-EP485491EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (lpxC) CSB-YP485492EON
CSB-EP485492EON
CSB-BP485492EON
CSB-MP485492EON
CSB-EP485492EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 Ribose-5-phosphate isomerase A (rpiA) CSB-YP485493EON
CSB-EP485493EON
CSB-BP485493EON
CSB-MP485493EON
CSB-EP485493EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 Putative Holliday junction resolvase (yqgF) CSB-YP485494EON
CSB-EP485494EON
CSB-BP485494EON
CSB-MP485494EON
CSB-EP485494EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 Aspartate 1-decarboxylase (panD) CSB-YP485495EON
CSB-EP485495EON
CSB-BP485495EON
CSB-MP485495EON
CSB-EP485495EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase (mtnN) CSB-YP485496EON
CSB-EP485496EON
CSB-BP485496EON
CSB-MP485496EON
CSB-EP485496EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 Outer membrane protein assembly factor yaeT (yaeT) CSB-YP485497EON
CSB-EP485497EON
CSB-BP485497EON
CSB-MP485497EON
CSB-EP485497EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 Probable sugar efflux transporter (sotB), partial CSB-YP485498EON
CSB-EP485498EON
CSB-BP485498EON
CSB-MP485498EON
CSB-EP485498EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 tRNA sulfurtransferase (thiI) CSB-YP485499EON
CSB-EP485499EON
CSB-BP485499EON
CSB-MP485499EON
CSB-EP485499EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 Acyl carrier protein phosphodiesterase (acpH) CSB-YP485500EON
CSB-EP485500EON
CSB-BP485500EON
CSB-MP485500EON
CSB-EP485500EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 Fatty acid metabolism regulator protein (fadR) CSB-YP485501EON
CSB-EP485501EON
CSB-BP485501EON
CSB-MP485501EON
CSB-EP485501EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 Zinc transporter ZupT (zupT), partial CSB-YP485502EON1
CSB-EP485502EON1
CSB-BP485502EON1
CSB-MP485502EON1
CSB-EP485502EON1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 Undecaprenyl-diphosphatase (uppP), partial CSB-YP485503EON1
CSB-EP485503EON1
CSB-BP485503EON1
CSB-MP485503EON1
CSB-EP485503EON1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 Uronate isomerase (uxaC) CSB-YP485504EON
CSB-EP485504EON
CSB-BP485504EON
CSB-MP485504EON
CSB-EP485504EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Escherichia coli O7:K1 HTH-type transcriptional regulator BetI (betI) CSB-YP485505EON
CSB-EP485505EON
CSB-BP485505EON
CSB-MP485505EON
CSB-EP485505EON-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://www.pptc.cn/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>